NumerixS Investment Technologies Inc Has $245,000 Stake in Innoviva Inc (INVA)

Share on StockTwits

NumerixS Investment Technologies Inc lifted its stake in shares of Innoviva Inc (NASDAQ:INVA) by 381.1% during the second quarter, HoldingsChannel reports. The firm owned 17,800 shares of the biotechnology company’s stock after acquiring an additional 14,100 shares during the quarter. NumerixS Investment Technologies Inc’s holdings in Innoviva were worth $245,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Affinity Investment Advisors LLC raised its stake in Innoviva by 14.2% in the 2nd quarter. Affinity Investment Advisors LLC now owns 32,086 shares of the biotechnology company’s stock valued at $443,000 after acquiring an additional 3,988 shares during the period. Schwab Charles Investment Management Inc. raised its stake in Innoviva by 1.0% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 422,680 shares of the biotechnology company’s stock valued at $7,047,000 after acquiring an additional 4,230 shares during the period. Aperio Group LLC raised its stake in Innoviva by 13.9% in the 2nd quarter. Aperio Group LLC now owns 37,228 shares of the biotechnology company’s stock valued at $514,000 after acquiring an additional 4,555 shares during the period. Municipal Employees Retirement System of Michigan raised its stake in Innoviva by 16.8% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 32,680 shares of the biotechnology company’s stock valued at $451,000 after acquiring an additional 4,690 shares during the period. Finally, Meritage Portfolio Management raised its stake in Innoviva by 1.9% in the 2nd quarter. Meritage Portfolio Management now owns 296,728 shares of the biotechnology company’s stock valued at $4,095,000 after acquiring an additional 5,457 shares during the period. Institutional investors own 72.69% of the company’s stock.

Shares of NASDAQ INVA opened at $14.56 on Friday. The company has a current ratio of 26.39, a quick ratio of 26.39 and a debt-to-equity ratio of -3.13. Innoviva Inc has a one year low of $11.47 and a one year high of $17.99. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of 9.54 and a beta of 2.26.

Innoviva (NASDAQ:INVA) last issued its quarterly earnings data on Thursday, July 26th. The biotechnology company reported $0.49 EPS for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.06). Innoviva had a net margin of 70.01% and a negative return on equity of 83.69%. The firm had revenue of $67.09 million during the quarter, compared to analyst estimates of $68.50 million. During the same period in the prior year, the company earned $0.30 earnings per share. The business’s quarterly revenue was up 14.6% compared to the same quarter last year. equities analysts forecast that Innoviva Inc will post 1.83 earnings per share for the current fiscal year.

In other Innoviva news, VP Theodore J. Jr. Witek sold 8,504 shares of the company’s stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $14.12, for a total value of $120,076.48. Following the transaction, the vice president now directly owns 256,271 shares of the company’s stock, valued at approximately $3,618,546.52. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.60% of the company’s stock.

INVA has been the topic of a number of research analyst reports. ValuEngine cut Innoviva from a “hold” rating to a “sell” rating in a research note on Tuesday, June 26th. BidaskClub upgraded Innoviva from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. Zacks Investment Research upgraded Innoviva from a “strong sell” rating to a “hold” rating in a research note on Tuesday, June 26th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and issued a $16.00 price objective on shares of Innoviva in a report on Monday, June 25th. Two analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $13.67.

Innoviva Profile

Innoviva, Inc engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI); ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI); and TRELEGY ELLIPTA (the combination FF/UMEC/VI).

See Also: Book Value Per Share in Stock Trading

Want to see what other hedge funds are holding INVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innoviva Inc (NASDAQ:INVA).

Institutional Ownership by Quarter for Innoviva (NASDAQ:INVA)

Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply